Indeed, the FDA-approved talimogene laherparepvec (T-VEC) encodes granulocyte-macrophage colony-stimulating factor (GM-CSF), which was designed, in part, to attract local DCs to initiate tumor-associated antigen presentation [25]. Here, CSF2 is linked to neoplasm.